News | News By Subject | News by Disease News By Date | Search News

Leukemia [Acute myelogenous leukemia (AML)] News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
4 Fatal Deaths in Seattle Genetics (SGEN)' Early-Stage Trials of AML Drug     12/30/2016
New York’s Cellectis (ALCLS) Looks to 2017 for Clinical Trials of AML Treatment     12/16/2016
FDA Places Clinical Hold on AML Drug Co-Developed by Johnson & Johnson (JNJ) and Genmab A/S (GEN.CO)     9/20/2016
Another Celgene (CELG) Bet Pays Off as Agios (AGIO) Eyes Early Approval of Leukemia Drug     9/8/2016
FDA Berates Celator Pharma (CPXX) for Pushing Unapproved Leukemia Drug to Doctors     9/8/2016
MEI Pharma (MSHL)'s Pracinostat Called a Breakthrough By the FDA     8/1/2016
Ultragenyx (RARE) Rising on Phase III Acute Myeloid Leukemia Data     7/15/2016
Celator Pharma (CPXX) Jumps on Breakthrough Therapy Win for Lead Cancer Drug     5/19/2016
3 Biotechs Getting Another Shot After Failed Trials     4/7/2016
Celator Pharma (CPXX) Stock Jumps 400% Premarket as AML Drug Wows in Phase III Study     3/16/2016
Akinion Halts Further Development of AKN-028 Due to Safety Concerns     3/4/2016
Forty Seven Launches with Half of $75 Million Series A Backed by Google (GOOG) and 100+ Patents     2/26/2016
Novartis AG (NVS)'s Leukemia Drug Gets Breakthrough Designation, Same Week as AstraZeneca PLC (AZN) and Roche (RHHBY) Drugs     2/22/2016
AbbVie (ABBV)'s Venetoclax Wins 3rd Breakthrough Tag from the FDA     1/28/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015

News from Around the Web
Less Is More With Acute Myeloid Leukemia Drug, Erasmus University Medical Center Study     3/17/2011
Mutations in Single Gene Predict Poor Outcomes in Adult Leukemia; Discovery May Guide Treatment for Acute Myeloid Leukemia, Washington University Study     11/11/2010
Protein That Predicts Prognosis Of Leukemia Patients May Also Be A Therapeutic Target, Whitehead Institute and Children's Hospital Boston Reveals     7/12/2010
Umbilical Cord Best Treatment for Childhood Leukaemia     6/8/2007
Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down     3/1/2007
Researchers Develop New Strategy For The Treatment Of CML     1/18/2007
Role For Proteomics In Identifying Hematologic Malignancies     1/11/2007
Study Identifies Molecular Process Underlying Leukemia     8/22/2006
Cytoplasmic Location Of Shuttling Protein Often Seen With AML     1/20/2005
Perpetual AML Can Arise From Rare Leukemic Stem Cell     6/1/2004
Gene Expression Profiling Yields Prognostic Information For AML Patients     4/14/2004

Press Releases
Regenacy Pharma Release: Pharma's HDAC1,2 Inhibitors Demonstrate Single-Agent And Synergistic Activity With Azacitidine (Vidaza) In Preclinical Models Of Acute Myeloid Leukemia     1/11/2017
MacroGenics (MGNX)’ MGD006 Granted Orphan Drug Status For AML By FDA     1/6/2017
Kura Oncology Receives FDA Clearance To Proceed With Clinical Trial For ERK Inhibitor KO-947 And Nominates KO-539 As Development Candidate For Menin-MLL Inhibitor Program     1/4/2017
Escend Pharma Receives Second Orphan Drug Designation From FDA For ES-3000     12/28/2016
Actinium (ATNM.OB) Announces Submission Of EU Orphan Designation Application For Actimab-A     12/13/2016
Cornerstone Pharmaceuticals, Inc. Presents Phase I Data On CPI-613 In Acute Myeloid Leukemia (AML) And T-Cell Non-Hodgkin's Lymphoma (T-Cell NHL) At American Society of Hematology 2016     12/6/2016
Sunesis (SNSS) Announces Presentation Of Updated Results From The VALOR Trial Examining Overall Survival In Patients Age 60 Years And Older With Relapsed/Refractory AML At The American Society of Hematology Annual Meeting     12/6/2016
Actinium (ATNM.OB) Highlights Results From Phase I Clinical Trial Of Actimab-A At 58th American Society of Hematology Annual Meeting     12/6/2016
Agios (AGIO) Announces New Clinical Data From Dose-Escalation Portion Of Phase I Trial Of Single Agent AG-120 Showing Durable Molecular Responses In Patients With Advanced Hematologic Malignancies     12/6/2016
Helsinn And MEI Pharma (MEIP) Report Prolongation Of Survival Results From Phase 2 Clinical Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia     12/5/2016
Daiichi Sankyo Presents Phase 1 Data For MDM2 Inhibitor DS-3032 In Acute Myeloid Leukemia And Myelodysplastic Syndrome At The 58th Annual Meeting Of The American Society of Hematology     12/5/2016
GlycoMimetics, Inc. (GLYC)' GMI-1271 Continues To Yield High Remission Rates, Favorable Tolerability In Two Phase II Arms Of Ongoing Phase I/II Clinical Trial For AML     12/5/2016
Karyopharm (KPTI) Presents Updated Phase II SAIL Relapsed/Refractory AML Clinical Data At The American Society of Hematology 2016 Annual Meeting     12/5/2016
Seattle Genetics (SGEN) Highlights Phase I Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy With HMAs, In Patients With Acute Myeloid Leukemia At American Society of Hematology Annual Meeting     12/5/2016
Syros Pharma Presents Data At American Society of Hematology Annual Meeting Further Supporting Clinical Potential Of Its First-In-Class Selective Rara Agonist For Genomically Defined Subsets Of AML And MDS Patients     12/5/2016

//-->